Louis Anthony Tartaglia

USPTO Granted Patents = 32 (Patent Applications = 6)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 2.0

ph-index = 9

Forward Citations = 200(Granted Patents)

Location History:

Waterstown, MA (US) (1998 - 1999)
Cambridge, MA (US) (2003)
Watertown, MA (US) (1997 - 2009)
Newton, MA (US) (2001 - 2023)

Company Filing History:

21 out of 850

Millennium Pharmaceuticals Limited

patents

4 out of 11

Rhythm Pharmaceuticals, Inc.

patents

2 out of 36

Millenium Pharmaceuticals, Inc.

patents

4. 2 out of 315

Whitehead Institute for Biomedical Research

patents

5. 1 out of 4

Ore Pharmaceuticals Inc.

patents

6. 3 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2023

Loading Chart...

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11702448 - Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers (2023-07-18),

2. 10954268 - Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers (2021-03-23),

3. 10167312 - Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers (2019-01-01),

4. 9845339 - Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers (2017-12-19),

5. 7842709 - Method for treating inflammatory diseases of the digestive tract (2010-11-30),

6. 7547515 - Methods for detection of the Ob receptor and the diagnosis of body weight disorders, including obesity and cachexia (2009-06-16),

7. 7033772 - Methods of identifying inhibitors of fatty acid transport proteins (FATP) (2006-04-25),

8. 6977240 - Methods of using the OB receptor antibodies to treat bodyweight disorders (2005-12-20),

9. 6933115 - Nucleic acid molecules encoding GLUTX and uses thereof (2005-08-23),

10. 6548269 - Ob receptor and methods for the diagnosis and treatment of body weight disorders, including obesity and cachexia (2003-04-15),

11. 6518402 - Antibodies to c5 polypeptides (2003-02-11),

12. 6509189 - Nucleic acid molecules encoding the cytoplasmic domain of human Ob receptor (2003-01-21),

13. 6506877 - Ob receptor (2003-01-14),

14. 6482927 - Chimeric proteins comprising the extracellular domain of murine Ob receptor (2002-11-19),

15. 6403552 - Ob receptor and methods for the diagnosis and treatment of body weight disorders (2002-06-11),

Title: Innovations of Louis Anthony Tartaglia in Melanocortin-4 Receptor Research

Introduction

Louis Anthony Tartaglia is a prominent inventor based in Watertown, MA, known for his significant contributions in the field of medical science. He holds an impressive portfolio of 32 patents, showcasing his commitment to innovation and improving therapeutic methods for various disorders.

Latest Patents

Among his latest inventions are patents related to the treatment of melanocortin-4 receptor-associated disorders in heterozygous carriers. These methods involve administering an effective amount of an agonist of the melanocortin-4 receptor (MC4R) to subjects who are heterozygous carriers of an MC4R mutation. This innovative approach aims to address disorders resulting from an attenuated response of MC4R to α-melanocortin stimulating hormone (α-MSH).

Career Highlights

Tartaglia has made a notable impact in the pharmaceutical industry through his work in companies such as Millennium Pharmaceuticals Limited and Rhythm Pharmaceuticals, Inc. His role in these organizations reflects his dedication to advancing medical sciences and ensuring the implementation of his patented methods in therapeutic settings.

Collaborations

Throughout his career, Louis Anthony Tartaglia has collaborated with esteemed professionals, including Robert I. Tepper and Janice A. Culpepper. These partnerships further exemplify the collaborative nature of scientific research and innovation.

Conclusion

Louis Anthony Tartaglia's innovations, especially in the realm of melanocortin-4 receptor disorders, demonstrate his significant role as an inventor and a contributor to the medical field. His continuous efforts and groundbreaking patents pave the way for future advancements in treatment strategies, benefiting countless individuals affected by such disorders.

This text is generated by artificial intelligence and may not be accurate.